Isolation and characterization of Lymphomycin

Nakao Ishida, Fujio Suzuki, Hiroshi Maeda, Katsuo Kumagai, Kensuke Ozu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A new antitumor antibiotic is produced in fermentation broths by Streptomyces sp. S-66. This material, named lymphomycin, was isolated on the basis of inhibition of mouse leukemia SN-36 in mice, and toxicity to BURKITT lymphoma cells in tissue culture. It was precipitated from filtered broth with ammonium sulfate and purified by chromatography on columns of Sephadex and carboxymethyl cellulose. Lymphomycin is a black-colored, acidic protein with a molecular weight of about 11, 000 and valine as an N-terminal amino-acid. It contains no carbohydrates or nucleic acids. It is soluble in water, insoluble in most organic solvents, and is relatively stable in water over the pH range, 5 to 7. It has no distinct absorption maximum in its spectrum. Lymphomycin has no inhibitory activity against bacteria, yeast, fungi and mycoplasmas tested so far. It is cytotoxic to Burkitt lymphoma and human lymphoblastoid cells and peritoneal macrophages, but not inhibitory to human epidermoid carcinoma HeLa, mouse fibroblast L, chick embryo, calf kidney and mouse adenocarcinoma FM3A cells in tissue culture. Lymphomycin is lethal to tumor-bearing mice at 80 mg/kg of body weight per day when given intraperitoneally once daily for 6 days, but not toxic at 40 mg/kg/day. Tests with transplanted rodent tumors indicate that the antibiotic is inhibitory to the growth of both solid and ascitic forms of Sarcoma 180 and lymphatic leukemia SN-36 in mice. The growth of solid tumor of a fibrosarcoma in hamsters was also inhibited at optimal daily doses of 0.8 and 2 mg/kg. Lymphomycin has no effect on the growth of the solid forms of Ehrlich and Bashford carcinoma in mice.

Original languageEnglish (US)
Pages (from-to)218-227
Number of pages10
JournalThe Journal of Antibiotics
Volume22
Issue number5
DOIs
StatePublished - 1969
Externally publishedYes

Fingerprint

Leukemia
Growth
Sarcoma 180
Anti-Bacterial Agents
Neoplasms
Carboxymethylcellulose Sodium
Burkitt Lymphoma
Water
Mycoplasma
Fibrosarcoma
Poisons
Valine
Ammonium Sulfate
Peritoneal Macrophages
Streptomyces
Chick Embryo
Renal Cell Carcinoma
Cricetinae
Nucleic Acids
Fermentation

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Isolation and characterization of Lymphomycin. / Ishida, Nakao; Suzuki, Fujio; Maeda, Hiroshi; Kumagai, Katsuo; Ozu, Kensuke.

In: The Journal of Antibiotics, Vol. 22, No. 5, 1969, p. 218-227.

Research output: Contribution to journalArticle

Ishida, Nakao ; Suzuki, Fujio ; Maeda, Hiroshi ; Kumagai, Katsuo ; Ozu, Kensuke. / Isolation and characterization of Lymphomycin. In: The Journal of Antibiotics. 1969 ; Vol. 22, No. 5. pp. 218-227.
@article{512cad0f9bc24c26a700ce3a4e532b40,
title = "Isolation and characterization of Lymphomycin",
abstract = "A new antitumor antibiotic is produced in fermentation broths by Streptomyces sp. S-66. This material, named lymphomycin, was isolated on the basis of inhibition of mouse leukemia SN-36 in mice, and toxicity to BURKITT lymphoma cells in tissue culture. It was precipitated from filtered broth with ammonium sulfate and purified by chromatography on columns of Sephadex and carboxymethyl cellulose. Lymphomycin is a black-colored, acidic protein with a molecular weight of about 11, 000 and valine as an N-terminal amino-acid. It contains no carbohydrates or nucleic acids. It is soluble in water, insoluble in most organic solvents, and is relatively stable in water over the pH range, 5 to 7. It has no distinct absorption maximum in its spectrum. Lymphomycin has no inhibitory activity against bacteria, yeast, fungi and mycoplasmas tested so far. It is cytotoxic to Burkitt lymphoma and human lymphoblastoid cells and peritoneal macrophages, but not inhibitory to human epidermoid carcinoma HeLa, mouse fibroblast L, chick embryo, calf kidney and mouse adenocarcinoma FM3A cells in tissue culture. Lymphomycin is lethal to tumor-bearing mice at 80 mg/kg of body weight per day when given intraperitoneally once daily for 6 days, but not toxic at 40 mg/kg/day. Tests with transplanted rodent tumors indicate that the antibiotic is inhibitory to the growth of both solid and ascitic forms of Sarcoma 180 and lymphatic leukemia SN-36 in mice. The growth of solid tumor of a fibrosarcoma in hamsters was also inhibited at optimal daily doses of 0.8 and 2 mg/kg. Lymphomycin has no effect on the growth of the solid forms of Ehrlich and Bashford carcinoma in mice.",
author = "Nakao Ishida and Fujio Suzuki and Hiroshi Maeda and Katsuo Kumagai and Kensuke Ozu",
year = "1969",
doi = "10.7164/antibiotics.22.218",
language = "English (US)",
volume = "22",
pages = "218--227",
journal = "Journal of Antibiotics",
issn = "0021-8820",
publisher = "Japan Antibiotics Research Association",
number = "5",

}

TY - JOUR

T1 - Isolation and characterization of Lymphomycin

AU - Ishida, Nakao

AU - Suzuki, Fujio

AU - Maeda, Hiroshi

AU - Kumagai, Katsuo

AU - Ozu, Kensuke

PY - 1969

Y1 - 1969

N2 - A new antitumor antibiotic is produced in fermentation broths by Streptomyces sp. S-66. This material, named lymphomycin, was isolated on the basis of inhibition of mouse leukemia SN-36 in mice, and toxicity to BURKITT lymphoma cells in tissue culture. It was precipitated from filtered broth with ammonium sulfate and purified by chromatography on columns of Sephadex and carboxymethyl cellulose. Lymphomycin is a black-colored, acidic protein with a molecular weight of about 11, 000 and valine as an N-terminal amino-acid. It contains no carbohydrates or nucleic acids. It is soluble in water, insoluble in most organic solvents, and is relatively stable in water over the pH range, 5 to 7. It has no distinct absorption maximum in its spectrum. Lymphomycin has no inhibitory activity against bacteria, yeast, fungi and mycoplasmas tested so far. It is cytotoxic to Burkitt lymphoma and human lymphoblastoid cells and peritoneal macrophages, but not inhibitory to human epidermoid carcinoma HeLa, mouse fibroblast L, chick embryo, calf kidney and mouse adenocarcinoma FM3A cells in tissue culture. Lymphomycin is lethal to tumor-bearing mice at 80 mg/kg of body weight per day when given intraperitoneally once daily for 6 days, but not toxic at 40 mg/kg/day. Tests with transplanted rodent tumors indicate that the antibiotic is inhibitory to the growth of both solid and ascitic forms of Sarcoma 180 and lymphatic leukemia SN-36 in mice. The growth of solid tumor of a fibrosarcoma in hamsters was also inhibited at optimal daily doses of 0.8 and 2 mg/kg. Lymphomycin has no effect on the growth of the solid forms of Ehrlich and Bashford carcinoma in mice.

AB - A new antitumor antibiotic is produced in fermentation broths by Streptomyces sp. S-66. This material, named lymphomycin, was isolated on the basis of inhibition of mouse leukemia SN-36 in mice, and toxicity to BURKITT lymphoma cells in tissue culture. It was precipitated from filtered broth with ammonium sulfate and purified by chromatography on columns of Sephadex and carboxymethyl cellulose. Lymphomycin is a black-colored, acidic protein with a molecular weight of about 11, 000 and valine as an N-terminal amino-acid. It contains no carbohydrates or nucleic acids. It is soluble in water, insoluble in most organic solvents, and is relatively stable in water over the pH range, 5 to 7. It has no distinct absorption maximum in its spectrum. Lymphomycin has no inhibitory activity against bacteria, yeast, fungi and mycoplasmas tested so far. It is cytotoxic to Burkitt lymphoma and human lymphoblastoid cells and peritoneal macrophages, but not inhibitory to human epidermoid carcinoma HeLa, mouse fibroblast L, chick embryo, calf kidney and mouse adenocarcinoma FM3A cells in tissue culture. Lymphomycin is lethal to tumor-bearing mice at 80 mg/kg of body weight per day when given intraperitoneally once daily for 6 days, but not toxic at 40 mg/kg/day. Tests with transplanted rodent tumors indicate that the antibiotic is inhibitory to the growth of both solid and ascitic forms of Sarcoma 180 and lymphatic leukemia SN-36 in mice. The growth of solid tumor of a fibrosarcoma in hamsters was also inhibited at optimal daily doses of 0.8 and 2 mg/kg. Lymphomycin has no effect on the growth of the solid forms of Ehrlich and Bashford carcinoma in mice.

UR - http://www.scopus.com/inward/record.url?scp=0014516160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014516160&partnerID=8YFLogxK

U2 - 10.7164/antibiotics.22.218

DO - 10.7164/antibiotics.22.218

M3 - Article

VL - 22

SP - 218

EP - 227

JO - Journal of Antibiotics

JF - Journal of Antibiotics

SN - 0021-8820

IS - 5

ER -